drugset / Trial / NCT01283048
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells. In this research study, the investigators are testing the safety to BKM-120 at different dose levels. The investigators will also be studying how well tolerated BKM-120 is, and how effective BKM-120 can be in the treatment of kidney cancer.
Timeline
- Start
- 2011-09
- Primary completion
- 2016-09
- Completion
- 2016-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | 60 mg | Oral |
| Subject | Buparlisib | Small molecule | 80 mg | Oral |
| Subject | Buparlisib | Small molecule | 100 mg | Oral |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |